Cardiogenic Shock Management in the Modern Era: A Narrative Review of Percutaneous Mechanical Circulatory Support...

Area of Science:

• Cardiology
• Critical Care Medicine
• Biomedical Engineering

Background:

• Cardiogenic shock (CS) presents a significant clinical challenge with high mortality rates.
• CS is characterized by impaired cardiac output leading to end-organ hypoperfusion, often stemming from acute myocardial infarction (AMI-CS) or heart failure exacerbations (HF-CS).
• The Society for Cardiovascular Angiography and Interventions (SCAI) classifies CS severity (Stages A-E) to guide treatment.

Purpose of the Study:

• To review current evidence on percutaneous mechanical circulatory support (MCS) devices for cardiogenic shock.
• To evaluate the clinical utility and efficacy of existing and emerging MCS technologies.
• To highlight future directions and ongoing trials in optimizing CS management.

Main Methods:

• Synthesis of current scientific literature and clinical trial data.
• Evaluation of various percutaneous MCS devices, including IABPs, Impella, TandemHeart, Protek-Duo, and VA-ECMO.
• Analysis of factors influencing device selection, such as shock severity, patient anatomy, comorbidities, and institutional resources.

Main Results:

• Advancements in percutaneous MCS have transformed CS management by providing targeted hemodynamic support.
• The DanGer-SHOCK trial indicated improved outcomes with early Impella use in anterior STEMI-associated CS.
• Device selection is multifactorial, requiring consideration of patient-specific and institutional factors.

Conclusions:

• Optimizing CS management requires individualized patient selection and evidence-based deployment of MCS.
• Multidisciplinary team collaboration is crucial for improving clinical outcomes in patients with CS.
• Ongoing research and clinical trials are essential for advancing the field of CS treatment.